Overview
FBLG market data
Price History
FBLG price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for FBLG. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
8-K filing — FibroBiologics, Inc. (FBLG)SEC EDGAR · Jul 9, 2026, 1:31 PM
FibroBiologics Completes Manufacturing Of Third Batch Of CYWC628 Drug Product For Ongoing Phase 1/2 Clinical Trial In Patients With Diabetic Foot UlcersBenzinga · Jul 7, 2026, 12:45 PM
FibroBiologics Commences Up To $9M Offering Of Common Shares, WarrantsBenzinga · Jun 26, 2026, 12:45 PM
FibroBiologics Receives U.S. Patent And Trademark Office Notice Of Allowance For Patented Application Entitled Therapeutic Use Of Fibroblasts In Wound HealingBenzinga · Jun 22, 2026, 12:35 PM
CORRECTION: FibroBiologics Announces Data From CYPS317 Study For Psoriasis Was Announced On May 22, 2026Benzinga · Jun 16, 2026, 12:45 PM
FibroBiologics Doses First Participant In Its Phase 1/2 Clinical Study Of CYWC628 To Treat Diabetic Foot UlcersBenzinga · Jun 16, 2026, 12:45 PM
FibroBiologics Announces Data From CYPS317 Study For Psoriasis Demonstrates HDF Spheroids And Single-Cell HDF Preparations Lower Disease Severity; Signification Reductions In PASI Scores SeenBenzinga · Jun 16, 2026, 12:40 PM
FibroBiologics Announces Preclinical Data From Its CYPS317 Program For Psoriasis Was Presented At The Society For Investigative Dermatology Meeting, May 13-15Benzinga · May 22, 2026, 12:40 PM
FibroBiologics Files New Provisional Patent Application With USPTO Titled 'Oral Fibroblasts And Fibroblast-Derived Therapeutics And Delivery Systems For Same'Benzinga · May 18, 2026, 12:40 PM
FibroBiologics Announces Strategic Expansion Of Its Fibroblast-Based Platform To Target HantavirusBenzinga · May 11, 2026, 12:32 PM